Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2022

The PRIMCAT cohort study: analysis of treatment utilisation, costs, and outcomes in Victoria for patients with cancer. (#335)

Fanny Franchini 1 2 , Karen Trapani 1 , Piers Gillett 1 , Koen Degeling 1 , Benjamin Daniels 3 , Sallie Pearson 3 , Ou Yang 1 , Yuting Zhang 1 , Peter Gibbs 4 , Ben Solomon 2 , Grant McArthur 2 , Jayesh Desai 2 , Stephen Fox 2 , Maarten IJzerman 1 2
  1. University of Melbourne, Melbourne, VICTORIA, Australia
  2. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
  3. University of New South Wales, Sydney, New South Wales, Australia
  4. Walter and Eliza Hall Research Institute, Melbourne, Victoria, Australia

Aims

The PRedicting the population health economic IMpact of new and current CAncer Treatments (PRIMCAT) is a MRFF-funded program that aims to estimate population health economic impact of new cancer treatments ahead of market approval. To achieve this, we first need to understand what the current landscape is. We established a Victorian-wide retrospective cohort study which will generate contemporary and timely evidence around the real-world utilisation, costs, and outcomes of cancer treatments for several cancers: melanoma, lung, colorectal, prostate, and breast.

Methods

The PRIMCAT cohort study comprises all adults aged 18 years and over who had a confirmed cancer diagnosis in Victoria between 2010–2019 (updated annually). These adults were identified from the Victorian Cancer Registry and data was linked to several datasets within the Centre for Victorian Data Linkage (Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset, Victorian Death Index, Elective Surgery Information System, Victorian Radiotherapy Minimum Dataset, Victorian Integrated Non-Admitted Health, Victorian Cost Data Collection). Once the cohort was established, the AIHW Data Linkage Unit further linked the records to Medicare Benefits Scheme, Pharmaceutical Benefits Scheme, and National Death Index.

Results

The cohort totals 180,721 adults across included cancer types, with breast and prostate cancers representing the majority (24% and 25.8%). We take a data-driven approach to analyse patients’ characteristics as well as diagnostics and treatment rates of the Victorian population by year/rurality. Treatment pathways are mapped by combining PBS and the Victorian-state datasets. Cost modelling is underway.

Conclusions

To date, the PRIMCAT cohort study represents the largest cancer-focused linked dataset of its kind in Australia and spans the entire continuum of care, enabling its in-depth analysis. This retrospective cohort study will provide evidence-based data to inform Health Technology Assessment (HTA) in Australia.